Francesco Paolo Schena

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1402390/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression. Journal of the American Society of Nephrology: JASN, 2022, 33, 291-303.	6.1	10
2	New directions in the pathogenesis of primary erythrocytosis in IgAN. EBioMedicine, 2022, 76, 103834.	6.1	0
3	Artificial intelligence in glomerular diseases. Pediatric Nephrology, 2022, 37, 2533-2545.	1.7	7
4	Randomized clinical study to evaluate the effect of personalized therapy on patients with immunoglobulin A nephropathy. CKJ: Clinical Kidney Journal, 2022, 15, 895-902.	2.9	6
5	FC048: New Tool to Predict the Clinical Course and Renal Failure in Patients with Immunoglobulin a Nephropathy. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	Ο
6	Prediction of chronic kidney disease and its progression by artificial intelligence algorithms. Journal of Nephrology, 2022, 35, 1953-1971.	2.0	13
7	Development and testing of an artificial intelligence tool for predicting end-stage kidney disease in patients with immunoglobulin A nephropathy. Kidney International, 2021, 99, 1179-1188.	5.2	47
8	Serum Levels of miR-148b and Let-7b at Diagnosis May Have Important Impact in the Response to Treatment and Long-Term Outcome in IgA Nephropathy. Journal of Clinical Medicine, 2021, 10, 1987.	2.4	11
9	MO260PERFORMANCE ANALYSIS OF AN ARTIFICIAL NEURAL NETWORK TOOL TO PREDICT ESKD IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IGAN). Nephrology Dialysis Transplantation, 2021, 36, .	0.7	1
10	Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis. American Journal of Kidney Diseases, 2021, 78, 340-349.e1.	1.9	28
11	Determination of hydroxytyrosol and tyrosol in human urine after intake of extra virgin olive oil produced with an ultrasounds-based technology. Journal of Pharmaceutical and Biomedical Analysis, 2021, 203, 114204.	2.8	3
12	The molecular mechanisms of inflammation and scarring in the kidneys of immunoglobulin A nephropathy. Seminars in Immunopathology, 2021, 43, 691-705.	6.1	8
13	β3 adrenergic receptor as potential therapeutic target in ADPKD. Physiological Reports, 2021, 9, e15058.	1.7	7
14	IgAN Genetic Risk Score in the Clinical Setting. Kidney International Reports, 2020, 5, 1627-1629.	0.8	0
15	Formalin-fixed paraffin-embedded renal biopsy tissues: an underexploited biospecimen resource for gene expression profiling in IgA nephropathy. Scientific Reports, 2020, 10, 15164.	3.3	13
16	COVID-19 and kidney transplantation: an Italian Survey and Consensus. Journal of Nephrology, 2020, 33, 667-680.	2.0	40
17	Immunosuppressive agents for treating IgA nephropathy. The Cochrane Library, 2020, 3, CD003965.	2.8	40
18	A Narrative Review on C3 Glomerulopathy: A Rare Renal Disease. International Journal of Molecular	4.1	21

Sciences, 2020, 21, 525.

2

#	Article	IF	CITATIONS
19	Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes and Endocrinology,the, 2019, 7, 128-139.	11.4	223
20	Catheter type, placement and insertion techniques for preventing catheter-related infections in chronic peritoneal dialysis patients. The Cochrane Library, 2019, 2019, CD004680.	2.8	14
21	Transcriptomics in kidney biopsy is an untapped resource for precision therapy in nephrology: a systematic review. Nephrology Dialysis Transplantation, 2018, 33, 1094-1102.	0.7	14
22	Epidemiology of IgA Nephropathy: A Global Perspective. Seminars in Nephrology, 2018, 38, 435-442.	1.6	204
23	Biomarkers and Precision Medicine in IgA Nephropathy. Seminars in Nephrology, 2018, 38, 521-530.	1.6	11
24	A transcriptomics study of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology, 2018, 142, 883-891.	2.9	18
25	Omics studies for comprehensive understanding of immunoglobulin A nephropathy: state-of-the-art and future directions. Nephrology Dialysis Transplantation, 2018, 33, 2101-2112.	0.7	23
26	Inhibin-A and Decorin Secreted by Human Adult Renal Stem/Progenitor Cells Through the TLR2 Engagement Induce Renal Tubular Cell Regeneration. Scientific Reports, 2017, 7, 8225.	3.3	28
27	Cultivar classification of Apulian olive oils: Use of artificial neural networks for comparing NMR, NIR and merceological data. Food Chemistry, 2017, 219, 131-138.	8.2	48
28	Renal Cell Carcinoma: A Study through NMR-Based Metabolomics Combined with Transcriptomics. Diseases (Basel, Switzerland), 2016, 4, 7.	2.5	62
29	The Three-Gene Signature in Urinary Extracellular Vesicles from Patients with Clear Cell Renal Cell Carcinoma. Journal of Cancer, 2016, 7, 1960-1967.	2.5	41
30	Clinical Application of Human Urinary Extracellular Vesicles in Kidney and Urologic Diseases. International Journal of Molecular Sciences, 2016, 17, 1043.	4.1	20
31	Potential role of effector memory T cells in chronic T cell-mediated kidney graft rejection. Nephrology Dialysis Transplantation, 2016, 31, 2131-2142.	0.7	17
32	Micropatterning control of tubular commitment in human adult renal stem cells. Biomaterials, 2016, 94, 57-69.	11.4	13
33	Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis. American Journal of Kidney Diseases, 2016, 68, 392-401.	1.9	85
34	Aberrantly methylated DNA regions lead to low activation of CD4+ T-cells in IgA nephropathy. Clinical Science, 2016, 130, 733-746.	4.3	39
35	MicroRNAs in Kidney Diseases. , 2016, , 107-138.		1
36	IgA nephropathy. Nature Reviews Disease Primers, 2016, 2, 16001.	30.5	322

#	Article	IF	CITATIONS
37	Nonadherence to immunosuppressive therapy in kidney transplant recipients: can technology help?. Journal of Nephrology, 2016, 29, 627-636.	2.0	27
38	Robustness of NMR-based metabolomics to generate comparable data sets for olive oil cultivar classification. An inter-laboratory study on Apulian olive oils. Food Chemistry, 2016, 199, 675-683.	8.2	38
39	Role of miR-422a and kallikrein-related peptidase 4 implicated in the development of lupus nephritis. Do we work in this direction?. Nephrology Dialysis Transplantation, 2016, 31, 683-685.	0.7	4
40	In a retrospective international study, circulating miR-148b and let-7b were found to be serum markers for detecting primary IgA nephropathy. Kidney International, 2016, 89, 683-692.	5.2	61
41	Clinical decision support system for end-stage kidney disease risk estimation in IgA nephropathy patients. Nephrology Dialysis Transplantation, 2016, 31, 80-86.	0.7	38
42	Immunosuppressive agents for treating IgA nephropathy. The Cochrane Library, 2015, , CD003965.	2.8	54
43	SP051EXOSOMAL SHUTTLE RNA IN URINARY EXTRACELLULAR VESICLES AS BIOMARKER OF CLEAR CELL RENAL CELL CARCINOMA. Nephrology Dialysis Transplantation, 2015, 30, iii397-iii397.	0.7	1
44	SP054ABNORMAL METHYLATED DNA REGIONS INDICATE AN ATYPICAL RESPONSE OF THE CD4+ T CELLS IN IGA NEPHROPATHY PATIENTS. Nephrology Dialysis Transplantation, 2015, 30, iii398-iii398.	0.7	0
45	Classification and chemometric study of Southern Italy monovarietal wines based on NMR and HPLC-DAD-MS. Food Science and Biotechnology, 2015, 24, 817-826.	2.6	32
46	Altered monocyte expression and expansion of non-classical monocyte subset in IgA nephropathy patients. Nephrology Dialysis Transplantation, 2015, 30, 1122-1132.	0.7	26
47	microRNAs in glomerular diseases from pathophysiology to potential treatment target. Clinical Science, 2015, 128, 775-788.	4.3	20
48	Role of let-7b in the regulation of <i>N</i> -acetylgalactosaminyltransferase 2 in IgA nephropathy. Nephrology Dialysis Transplantation, 2015, 30, 1132-1139.	0.7	60
49	Potential Reparative Role of Resident Adult Renal Stem/Progenitor Cells in Acute Kidney Injury. BioResearch Open Access, 2015, 4, 326-333.	2.6	21
50	Patient classification and outcome prediction in IgA nephropathy. Computers in Biology and Medicine, 2015, 66, 278-286.	7.0	19
51	Genome-wide scan identifies a copy number variable region at 3p21.1 that influences the TLR9 expression levels in IgA nephropathy patients. European Journal of Human Genetics, 2015, 23, 940-948.	2.8	23
52	MicroRNAs in Kidney Diseases. , 2015, , 1-32.		0
53	Following the olive oil production chain: 1D and 2D NMR study of olive paste, pomace, and oil. European Journal of Lipid Science and Technology, 2014, 116, 1513-1521.	1.5	18
54	Biomarkers and personalized therapy in chronic kidney diseases. Expert Opinion on Investigational Drugs, 2014, 23, 1051-1054.	4.1	6

#	Article	IF	CITATIONS
55	MicroRNAs in kidney diseases: new promising biomarkers for diagnosis and monitoring. Nephrology Dialysis Transplantation, 2014, 29, 755-763.	0.7	72
56	A Bioartificial Renal Tubule Device Embedding Human Renal Stem/Progenitor Cells. PLoS ONE, 2014, 9, e87496.	2.5	69
57	A Critical Revision of the Supportive Therapy in IgA Nephropathy. Juntendo Medical Journal, 2014, 60, 251-257.	0.1	Ο
58	A proton nuclear magnetic resonance-based metabolomic approach in IgA nephropathy urinary profiles. Metabolomics, 2013, 9, 740-751.	3.0	11
59	Risk of de novo cancers after transplantation: Results from a cohort of 7217 kidney transplant recipients, Italy 1997–2009. European Journal of Cancer, 2013, 49, 336-344.	2.8	157
60	A comparative study of covariance selection models for the inference of gene regulatory networks. Journal of Biomedical Informatics, 2013, 46, 894-904.	4.3	12
61	An end stage kidney disease predictor based on an artificial neural networks ensemble. Expert Systems With Applications, 2013, 40, 4438-4445.	7.6	60
62	From -omics to personalized medicine in nephrology: integration is the key. Nephrology Dialysis Transplantation, 2013, 28, 24-28.	0.7	29
63	<scp>NMR</scp> â€based metabolomic approach for <scp>EVOO</scp> from secular olive trees of Apulia region. European Journal of Lipid Science and Technology, 2013, 115, 1043-1052.	1.5	15
64	Human renal stem/progenitor cells repair tubular epithelial cell injury through TLR2-driven inhibin-A and microvesicle-shuttled decorin. Kidney International, 2013, 83, 392-403.	5.2	57
65	Monitoring of Inosine Monophosphate Dehydrogenase Activity and Expression during the Early Period of Mycophenolate Mofetil Therapy in De Novo Renal Transplant Patients. Drug Metabolism and Pharmacokinetics, 2013, 28, 109-117.	2.2	14
66	A Randomized, Open-Label Study of Sirolimus Versus Cyclosporine in Primary De Novo Renal Allograft Recipients. Transplantation, 2013, 95, 1233-1241.	1.0	38
67	Downregulation of Nuclear-Encoded Genes of Oxidative Metabolism in Dialyzed Chronic Kidney Disease Patients. PLoS ONE, 2013, 8, e77847.	2.5	58
68	miR-1915 and miR-1225-5p Regulate the Expression of CD133, PAX2 and TLR2 in Adult Renal Progenitor Cells. PLoS ONE, 2013, 8, e68296.	2.5	46
69	Increasing relevance of donor-specific antibodies in antibody-mediated rejection. Journal of Nephrology, 2013, 26, 237-242.	2.0	14
70	BMP-2 induces a profibrotic phenotype in adult renal progenitor cells through Nox4 activation. American Journal of Physiology - Renal Physiology, 2012, 303, F23-F34.	2.7	33
71	Search for genetic association between IgA nephropathy and candidate genes selected by function or by gene mapping at loci IGAN2 and IGAN3. Nephrology Dialysis Transplantation, 2012, 27, 2328-2337.	0.7	16
72	Abnormal miR-148b Expression Promotes Aberrant Glycosylation of IgA1 in IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2012, 23, 814-824.	6.1	176

#	Article	IF	CITATIONS
73	Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study. Nephrology Dialysis Transplantation, 2012, 27, 3560-3567.	0.7	49
74	Transplantation - basic. Nephrology Dialysis Transplantation, 2012, 27, ii517-ii524.	0.7	1
75	Activated innate immunity and the involvement of CX3CR1–fractalkine in promoting hematuria in patients with IgA nephropathy. Kidney International, 2012, 82, 548-560.	5.2	48
76	Thrombin induces complement production and modulates T cell responses by dendritic cells (DCs) in kidney transplant recipients with delayed graft function (DGF). Immunobiology, 2012, 217, 1214.	1.9	0
77	Coagulation Activation Is Associated with Nicotinamide Adenine Dinucleotide Phosphate Oxidase-Dependent Reactive Oxygen Species Generation in Hemodialysis Patients. Antioxidants and Redox Signaling, 2012, 16, 428-439.	5.4	10
78	1H Nuclear Magnetic Resonance Study of Olive Oils Commercially Available as Italian Products in the United States of America. Nutrients, 2012, 4, 343-355.	4.1	41
79	Reply: The Importance of Testing Anti-IL-17 Antibodies from Different Suppliers. American Journal of Transplantation, 2012, 12, 506.	4.7	0
80	The possible role of ChemR23/Chemerin axis in the recruitment of dendritic cells in lupus nephritis. Kidney International, 2011, 79, 1228-1235.	5.2	71
81	Lower Malignancy Rates in Renal Allograft Recipients Converted to Sirolimus-Based, Calcineurin Inhibitor-Free Immunotherapy: 24-Month Results From the CONVERT Trial. Transplantation, 2011, 92, 303-310.	1.0	198
82	Sirolimus and Proteinuria in Renal Transplant Patients: Evidence for a Dose-Dependent Effect on Slit Diaphragm-Associated Proteins. Transplantation, 2011, 91, 997-1004.	1.0	58
83	T helper 1, 2 and 17 cell subsets in renal transplant patients with delayed graft function. Transplant International, 2011, 24, 233-242.	1.6	39
84	IL-17 Expression by Tubular Epithelial Cells in Renal Transplant Recipients with Acute Antibody-Mediated Rejection. American Journal of Transplantation, 2011, 11, 1248-1259.	4.7	65
85	Rapamycin-Induced Hypophosphatemia and Insulin Resistance Are Associated With mTORC2 Activation and Klotho Expression. American Journal of Transplantation, 2011, 11, 1656-1664.	4.7	45
86	Desmopressin Acetate in Percutaneous Ultrasound-Guided Kidney Biopsy: A Randomized Controlled Trial. American Journal of Kidney Diseases, 2011, 57, 850-855.	1.9	93
87	Management of patients with chronic kidney disease. Internal and Emergency Medicine, 2011, 6, 77-83.	2.0	25
88	Multivariate Analysis of 1H-NMR Spectra of Genetically Characterized Extra Virgin Olive Oils and Growth Soil Correlations. JAOCS, Journal of the American Oil Chemists' Society, 2011, 88, 1463-1475.	1.9	33
89	AQP5 Is Expressed In Type-B Intercalated Cells in the Collecting Duct System of the Rat, Mouse and Human Kidney. Cellular Physiology and Biochemistry, 2011, 28, 683-692.	1.6	48
90	Cryoglobulinemic membranoproliferative glomerulonephritis: beyond conventional therapy. Clinical Nephrology, 2011, 75, 374-379.	0.7	14

#	Article	IF	CITATIONS
91	α- and β-Adducin polymorphisms affect podocyte proteins and proteinuria in rodents and decline of renal function in human IgA nephropathy. Journal of Molecular Medicine, 2010, 88, 203-217.	3.9	19
92	Pharmacogenomics: a new paradigm to personalize treatments in nephrology patients. Clinical and Experimental Immunology, 2010, 159, 268-280.	2.6	23
93	High pretransplant serum levels of CXCL9 are associated with increased risk of acute rejection and graft failure in kidney graft recipients. Transplant International, 2010, 23, 465-475.	1.6	33
94	TLR2 plays a role in the activation of human resident renal stem/progenitor cells. FASEB Journal, 2010, 24, 514-525.	0.5	107
95	The Anti-Fibrotic Effect of Mycophenolic Acid–Induced Neutral Endopeptidase. Journal of the American Society of Nephrology: JASN, 2010, 21, 2157-2168.	6.1	19
96	Worldwide distribution of glomerular diseases: the role of renal biopsy registries. Nephrology Dialysis Transplantation, 2010, 25, 334-336.	0.7	51
97	The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney International, 2010, 77, 921-927.	5.2	181
98	Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrology Dialysis Transplantation, 2010, 25, 1363-1364.	0.7	1
99	Immunohistochemical characterization of glomerular and tubulointerstitial infiltrates in renal transplant patients with chronic allograft dysfunction. Nephrology Dialysis Transplantation, 2010, 25, 4071-4077.	0.7	16
100	Infiltrating dendritic cells contribute to local synthesis of C1q in murine and human lupus nephritis. Molecular Immunology, 2010, 47, 2129-2137.	2.2	60
101	Extended Criteria Donor Kidney Transplantation: Comparative Outcome Analysis Between Single versus Double Kidney Transplantation at 5 Years. Transplantation Proceedings, 2010, 42, 1104-1107.	0.6	36
102	Pentraxin 3 and complement cascade activation in the failure of arteriovenous fistula. Atherosclerosis, 2010, 209, 241-247.	0.8	21
103	Bone morphogenetic protein-2 may represent the molecular link between oxidative stress and vascular stiffness in chronic kidney disease. Atherosclerosis, 2010, 211, 418-423.	0.8	56
104	Therapeutic Targeting of Classical and Lectin Pathways of Complement Protects from Ischemia-Reperfusion-Induced Renal Damage. American Journal of Pathology, 2010, 176, 1648-1659.	3.8	136
105	Altered modulation of WNT–β-catenin and PI3K/Akt pathways in IgA nephropathy. Kidney International, 2010, 78, 396-407.	5.2	78
106	The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney International, 2009, 76, 546-556.	5.2	892
107	Genome-wide association studies in kidney diseases: Quo Vadis?. Nephrology Dialysis Transplantation, 2009, 24, 3589-3592.	0.7	2
108	Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrology Dialysis Transplantation, 2009, 24, 3694-3701.	0.7	256

#	Article	IF	CITATIONS
109	Epidemiology and Ancestral Difference. , 2009, , 9-19.		7
110	Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease. BMC Genomics, 2009, 10, 388.	2.8	202
111	ID2-VEGF-related Pathways in the Pathogenesis of Kaposi's Sarcoma: A Link Disrupted by Rapamycin. American Journal of Transplantation, 2009, 9, 558-566.	4.7	18
112	IgA Nephropathy: A Disease in Search of a Large-Scale Clinical Trial to Reliably Inform Practice. American Journal of Kidney Diseases, 2009, 53, 5-8.	1.9	25
113	Serum Fetuin A in Hemodialysis: A Link Between Derangement of Calcium-Phosphorus Homeostasis and Progression of Atherosclerosis?. American Journal of Kidney Diseases, 2009, 53, 467-474.	1.9	23
114	The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney International, 2009, 76, 534-545.	5.2	1,028
115	Conversion From Calcineurin Inhibitors to Sirolimus Maintenance Therapy in Renal Allograft Recipients: 24-Month Efficacy and Safety Results From the CONVERT Trial. Transplantation, 2009, 87, 233-242.	1.0	524
116	Review of Symposium. Transplantation, 2009, 87, S30-S33.	1.0	6
117	Genetic variant of C1GalT1 contributes to the susceptibility to IgA nephropathy. Journal of Nephrology, 2009, 22, 152-9.	2.0	30
118	Kaposi's sarcoma and mTOR: a crossroad between viral infection neoangiogenesis and immunosuppression. Transplant International, 2008, 21, 825-832.	1.6	37
119	A Randomized, Multicenter Study of Steroid Avoidance, Early Steroid Withdrawal or Standard Steroid Therapy in Kidney Transplant Recipients. American Journal of Transplantation, 2008, 8, 307-316.	4.7	274
120	Acute rejection of non-functional allograft in kidney transplant recipients with hepatitis C treated with peginterferon alpha-2a: Reply. Journal of Hepatology, 2008, 49, 462-463.	3.7	1
121	Immature myeloid and plasmacytoid dendritic cells infiltrate renal tubulointerstitium in patients with lupus nephritis. Molecular Immunology, 2008, 45, 259-265.	2.2	121
122	Dialysis-related systemic microinflammation is associated with specific genomic patterns. Nephrology Dialysis Transplantation, 2008, 23, 1673-1681.	0.7	32
123	The dynamics of kidney donation: Viewpoints from the donor, the recipients, and the transplant team. Kidney International, 2008, 73, 1108-1110.	5.2	8
124	The ratio of epidermal growth factor to monocyte chemotactic peptide-1 in the urine predicts renal prognosis in IgA nephropathy. Kidney International, 2008, 73, 327-333.	5.2	94
125	No evidence for a role of cosmc-chaperone mutations in European IgA nephropathy patients. Nephrology Dialysis Transplantation, 2008, 24, 321-324.	0.7	30
126	Response to †The importance of donor privacy'. Kidney International, 2008, 74, 1359.	5.2	0

#	Article	IF	CITATIONS
127	Increase of Proliferating Renal Progenitor Cells in Acute Tubular Necrosis Underlying Delayed Graft Function. Transplantation, 2008, 85, 1112-1119.	1.0	50
128	Rapamycin Inhibits PAI-1 Expression and Reduces Interstitial Fibrosis and Glomerulosclerosis in Chronic Allograft Nephropathy. Transplantation, 2008, 85, 125-134.	1.0	49
129	Rituximab induces complete remission in a case of membranous nephropathy associated with hepatitis C virus- related infection. Nephrology Dialysis Transplantation, 2007, 22, 3674-3676.	0.7	2
130	A randomized exploratory trial of steroid avoidance in renal transplant patients treated with everolimus and low-dose cyclosporine. Nephrology Dialysis Transplantation, 2007, 23, 707-714.	0.7	39
131	Current structure and organization for renal patient assistance in Italy. Nephrology Dialysis Transplantation, 2007, 23, 1323-1329.	0.7	5
132	Kaposi's sarcoma in renal transplant recipientsthe impact of proliferation signal inhibitors. Nephrology Dialysis Transplantation, 2007, 22, i17-i22.	0.7	82
133	Analysis of the factors conditioning the diffusion of peritoneal dialysis in Italy. Nephrology Dialysis Transplantation, 2007, 22, 3601-3605.	0.7	18
134	Ischemia–reperfusion injury-induced abnormal dendritic cell traffic in the transplanted kidney with delayed graft function. Kidney International, 2007, 72, 994-1003.	5.2	43
135	FTY720 Versus Mycophenolate Mofetil in De Novo Renal Transplantation: Six-Month Results of a Double-Blind Study. Transplantation, 2007, 84, 885-892.	1.0	57
136	A comparison of DNA extraction methods for food analysis. Food Control, 2007, 18, 76-80.	5.5	132
137	The treatment of chronic hepatitis C with peginterferon alfa-2a (40kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. Journal of Hepatology, 2007, 46, 768-774.	3.7	163
138	Local Activation of Interleukin 6 Signaling Is Associated With Arteriovenous Fistula Stenosis in Hemodialysis Patients. American Journal of Kidney Diseases, 2007, 49, 664-673.	1.9	36
139	Immune modulation of human dendritic cells by complement. European Journal of Immunology, 2007, 37, 2803-2811.	2.9	67
140	Dexamethasone modulates interleukinâ€12 production by inducing monocyte chemoattractant proteinâ€1 in human dendritic cells. Immunology and Cell Biology, 2007, 85, 610-616.	2.3	18
141	A Novel Simpler Histological Classification for Renal Survival in IgA Nephropathy: A Retrospective Study. American Journal of Kidney Diseases, 2007, 49, 763-775.	1.9	153
142	Monitoring Biological Action of Rapamycin in Renal Transplantation. American Journal of Kidney Diseases, 2007, 50, 314-325.	1.9	25
143	PDGF-B gene single-nucleotide polymorphisms are not predictive for disease onset or progression of IgA nephropathy. Clinical Nephrology, 2007, 67, 65-72.	0.7	6
144	Genetic Heterogeneity in Italian Families with IgA Nephropathy: Suggestive Linkage for Two Novel IgA Nephropathy Loci. American Journal of Human Genetics, 2006, 79, 1130-1134.	6.2	111

#	Article	IF	CITATIONS
145	Sirolimus Interferes with Iron Homeostasis in Renal Transplant Recipients. Transplantation, 2006, 82, 908-912.	1.0	62
146	Role of interferon-Î ³ gene polymorphisms in susceptibility to IgA nephropathy: a family-based association study. European Journal of Human Genetics, 2006, 14, 488-496.	2.8	43
147	Cis and trans regulatory elements in NPHS2 promoter: Implications in proteinuria and progression of renal diseases. Kidney International, 2006, 70, 1332-1341.	5.2	16
148	FTY720 versus MMF with Cyclosporine in de novo Renal Transplantation: A 1-Year, Randomized Controlled Trial in Europe and Australasia. American Journal of Transplantation, 2006, 6, 2912-2921.	4.7	145
149	lgA Nephropathy: The Presence of Familial Disease Does Not Confer an Increased Risk for Progression. American Journal of Kidney Diseases, 2006, 47, 761-769.	1.9	23
150	Confocal Laser Scanning Microscope Study of Terminal Villi Vessels in Normal Term and Pre-eclamptic Placentas. Placenta, 2006, 27, 735-739.	1.5	33
151	The urinary sediment beyond light microscopical examination. Nephrology Dialysis Transplantation, 2006, 21, 1482-1485.	0.7	10
152	Role of Blood Pressure Targets and Specific Antihypertensive Agents Used to Prevent Diabetic Nephropathy and Delay Its Progression: Table 1 Journal of the American Society of Nephrology: JASN, 2006, 17, S153-S155.	6.1	58
153	CD40L Proinflammatory and Profibrotic Effects on Proximal Tubular Epithelial Cells. Journal of the American Society of Nephrology: JASN, 2006, 17, 627-636.	6.1	37
154	LCAT deficiency: molecular and phenotypic characterization of an Italian family. Journal of Nephrology, 2006, 19, 375-81.	2.0	8
155	Evidence for optimal hemoglobin targets in chronic kidney disease. Journal of Nephrology, 2006, 19, 640-7.	2.0	5
156	Efficacy and Safety Outcomes Among De Novo Renal Transplant Recipients Managed by C2 Monitoring of Cyclosporine A Microemulsion: Results of a 12-Month, Randomized, Multicenter Study. Transplantation, 2005, 79, 577-583.	1.0	42
157	Superior Outcomes in Renal Transplantation after Early Cyclosporine Withdrawal and Sirolimus Maintenance Therapy, Regardless of Baseline Renal Function. Transplantation, 2005, 80, 1204-1211.	1.0	52
158	Hepatitis C virus RNA and core protein in kidney glomerular and tubular structures isolated with laser capture microdissection. Clinical and Experimental Immunology, 2005, 140, 498-506.	2.6	92
159	Vasoactive intestinal polypeptide (VIP) is not an androgen-dependent neuromediator of penile erection. International Journal of Impotence Research, 2005, 17, 23-26.	1.8	15
160	Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab. Arthritis and Rheumatism, 2005, 52, 2519-2520.	6.7	48
161	The IgA nephropathy Biobank. An important starting point for the genetic dissection of a complex trait. BMC Nephrology, 2005, 6, 14.	1.8	24
162	Coagulation Cascade Activation Causes CC Chemokine Receptor-2 Gene Expression and Mononuclear Cell Activation in Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2005, 16, 2477-2486.	6.1	19

Francesco Paolo Schena

#	Article	IF	CITATIONS
163	Antihypertensive Agents for Primary Prevention of Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2005, 16, 3081-3091.	6.1	74
164	In Vivo Modulation of Soluble "Antagonistic―IL-6 Receptor Synthesis and Release in ESRD. Journal of the American Society of Nephrology: JASN, 2005, 16, 1099-1107.	6.1	27
165	Rapamycin for Treatment of Chronic Allograft Nephropathy in Renal Transplant Patients. Journal of the American Society of Nephrology: JASN, 2005, 16, 3755-3762.	6.1	115
166	CD40 Ligand Increases Complement C3 Secretion by Proximal Tubular Epithelial Cells. Journal of the American Society of Nephrology: JASN, 2005, 16, 2003-2011.	6.1	23
167	Thin glomerular basement membrane disease: clinical significance of a morphological diagnosisa collaborative study of the Italian Renal Immunopathology Group. Nephrology Dialysis Transplantation, 2005, 20, 545-551.	0.7	26
168	Inflammation and carnitine in hemodialysis patients. , 2005, 15, 8-12.		26
169	A general multiplex-PCR assay for the general detection of genetically modified soya and maize. Food Control, 2005, 16, 535-539.	5.5	87
170	A Randomized Trial of Steroid Avoidance in Renal Transplant Patients Treated with Everolimus and Cyclosporine. Transplantation Proceedings, 2005, 37, 788-790.	0.6	22
171	Sirolimus-Based Therapy With or Without Cyclosporine: Long-Term Follow-up in Renal Transplant Patients. Transplantation Proceedings, 2005, 37, 693-696.	0.6	26
172	Pathogenetic Mechanisms of Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2005, 16, S30-S33.	6.1	463
173	Sirolimus for Kaposi's Sarcoma in Renal-Transplant Recipients. New England Journal of Medicine, 2005, 352, 1317-1323.	27.0	924
174	One-year angiotensin-converting enzyme inhibition plus mycophenolate mofetil immunosuppression in the course of early IgA nephropathy: a multicenter, randomised, controlled study. Journal of Nephrology, 2005, 18, 136-40.	2.0	18
175	Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ: British Medical Journal, 2004, 329, 828.	2.3	318
176	Long-Term Benefits with Sirolimus-Based Therapy after Early Cyclosporine Withdrawal. Journal of the American Society of Nephrology: JASN, 2004, 15, 809-817.	6.1	221
177	The Number, Quality, and Coverage of Randomized Controlled Trials in Nephrology. Journal of the American Society of Nephrology: JASN, 2004, 15, 411-419.	6.1	285
178	Ischemia-Reperfusion Induces Glomerular and Tubular Activation of Proinflammatory and Antiapoptotic Pathways. Journal of the American Society of Nephrology: JASN, 2004, 15, 2675-2686.	6.1	91
179	Addition of Sirolimus to Cyclosporine Delays the Recovery from Delayed Graft Function but Does not Affect 1-Year Graft Function. Journal of the American Society of Nephrology: JASN, 2004, 15, 228-233.	6.1	87
180	Catheter-Related Interventions to Prevent Peritonitis in Peritoneal Dialysis. Journal of the American Society of Nephrology: JASN, 2004, 15, 2735-2746.	6.1	161

#	Article	IF	CITATIONS
181	Sirolimus and angiotensin-converting enzyme inhibitors together induce tongue oedema in renal transplant recipients. Nephrology Dialysis Transplantation, 2004, 19, 2906-2908.	0.7	22
182	Hemoglobin Targets for the Anemia of Chronic Kidney Disease: A Meta-analysis of Randomized, Controlled Trials. Journal of the American Society of Nephrology: JASN, 2004, 15, 3154-3165.	6.1	142
183	Immunosuppressive treatments for immunoglobulin A nephropathy: A metaâ€analysis of randomized controlled trials. Nephrology, 2004, 9, 177-185.	1.6	76
184	jun-N-terminal kinase regulates thrombin-induced PAI-1 gene expression in proximal tubular epithelial cells. Kidney International, 2004, 65, 2249-2261.	5.2	25
185	The Italian experience of the national registry of renal biopsies. Kidney International, 2004, 66, 890-894.	5.2	132
186	Predictors of bleeding complications in percutaneous ultrasound-guided renal biopsy. Kidney International, 2004, 66, 1570-1577.	5.2	243
187	Medical and surgical complications after kidney transplantation from "suboptimal donors― one centre's experience. Transplantation Proceedings, 2004, 36, 493-494.	0.6	11
188	Dendritic cells and complement: at the cross road of innate and adaptive immunity. Molecular Immunology, 2004, 41, 133-140.	2.2	36
189	EARLY WITHDRAWAL OF CYCLOSPORINE IMPROVES 1-YEAR KIDNEY GRAFT STRUCTURE AND FUNCTION IN SIROLIMUS-TREATED PATIENTS: RESPONSE TO THE AUTHORS. Transplantation, 2004, 77, 162-163.	1.0	1
190	Maturation of dendritic cells abrogates C1q production in vivo and in vitro. Blood, 2004, 103, 3813-3820.	1.4	157
191	Conversion to C2 monitoring of cyclosporine A exposure in maintenance kidney transplant recipients: Results at 3 years. American Journal of Kidney Diseases, 2004, 44, 886-892.	1.9	13
192	Conversion to C2 monitoring of cyclosporine A exposure in maintenance kidney transplant recipients: Results at 3 years. American Journal of Kidney Diseases, 2004, 44, 886-892.	1.9	8
193	Antimicrobial agents to prevent peritonitis in peritoneal dialysis: a systematic review of randomized controlled trials. American Journal of Kidney Diseases, 2004, 44, 591-603.	1.9	43
194	An "evidence-based―survey of therapeutic options for IgA nephropathy: assessment and criticism. American Journal of Kidney Diseases, 2003, 41, 1129-1139.	1.9	70
195	The role of hyperparathyroidism, erythropoietin therapy, and CMV infection in the failure of arteriovenous fistula in hemodialysis. Kidney International, 2003, 64, 715-719.	5.2	43
196	Protease-Activated Receptor-2 Expression in IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2003, 14, 2072-2083.	6.1	73
197	Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients. Transplantation, 2003, 75, 998-1003.	1.0	74
198	Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion. Transplantation, 2003, 76, 903-908.	1.0	103

1

#	Article	IF	CITATIONS
199	Immunosuppressive agents for treating IgA nephropathy. , 2003, , CD003965.		18
200	MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma. Clinical Cancer Research, 2003, 9, 947-54.	7.0	51
201	Clinical and therapeutic aspects of diabetic nephropathy. Journal of Nephrology, 2003, 16, 487-99.	2.0	19
202	Stem cells: reparative medicine and nephrology. Journal of Nephrology, 2003, 16 Suppl 7, S1-5.	2.0	1
203	Disease-associated Bias in T Helper Type 1 (Th1)/Th2 CD4+ T Cell Responses Against MAGE-6 in HLA-DRB1*0401+ Patients With Renal Cell Carcinoma or Melanoma. Journal of Experimental Medicine, 2002, 196, 619-628.	8.5	290
204	Captopril enhances transforming growth factor (tgf)-??1 expression in peripheral blood mononuclear cells: a mechanism independent from angiotensin converting enzyme inhibition? A study in cyclosporine-treated kidney-transplanted patients. Transplantation, 2002, 74, 1710-1715.	1.0	16
205	Hypertension is an independent predictor of delayed graft function and worse renal function only in kidneys with chronic pathological lesions. Transplantation, 2002, 73, 623-627.	1.0	34
206	Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination1, 2. Transplantation, 2002, 74, 1560-1567.	1.0	158
207	Primary cerebral lymphoma and membranous nephropathy: A still unreported association. American Journal of Kidney Diseases, 2002, 39, e22.1-e22.5.	1.9	7
208	Pregnancy in renal transplantation: immunologic evaluation of neonates from mothers with transplanted kidney. Transplant Immunology, 2002, 9, 161-164.	1.2	25
209	Vitamin E-modified filters modulate Jun N-terminal kinase activation in peripheral blood mononuclear cells. Kidney International, 2002, 62, 602-610.	5.2	24
210	For further investigations in IgA nephropathy the approach from phenotype to genotype is welcome. Clinical and Experimental Immunology, 2002, 127, 399-401.	2.6	4
211	Therapeutic aspects of IgA nephropathy: an overview. Nephrology, 2002, 7, S156-S163.	1.6	0
212	Therapeutic aspects of IgA nephropathy: an overview. Nephrology, 2002, 7, S156.	1.6	1
213	Increased Risk of End-Stage Renal Disease in Familial IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2002, 13, 453-460.	6.1	71
214	Preeclampsia and fetal triploidy: a rarely reported association in nephrologic literature. Journal of Nephrology, 2002, 15, 74-8.	2.0	4
215	Immunoglobulin a nephropathy with mild renal lesions: a call in the forest for physicians and nephrologists. American Journal of Medicine, 2001, 110, 499-500.	1.5	29

Angiotensin IV and Renal Diseases. , 2001, 135, 63-71.

#	Article	IF	CITATIONS
217	PROTEASE-ACTIVATED RECEPTOR 1 AND PLASMINOGEN ACTIVATOR INHIBITOR 1 EXPRESSION IN CHRONIC ALLOGRAFT NEPHROPATHY. Transplantation, 2001, 72, 1437-1443.	1.0	52
218	ACE gene polymorphism and IgA nephropathy: An ethnically homogeneous study and a meta-analysis. Kidney International, 2001, 60, 732-740.	5.2	66
219	THE ROLE OF TUBULAR CELLS IN THE PROGRESSION OF RENAL DAMAGE: GUILTY OR INNOCENT?. Renal Failure, 2001, 23, 589-596.	2.1	10
220	Activated Coagulation Factor X: A Novel Mitogenic Stimulus for Human Mesangial Cells. Journal of the American Society of Nephrology: JASN, 2001, 12, 891-899.	6.1	14
221	MCP-1 and EGF renal expression and urine excretion in human congenital obstructive nephropathy. Kidney International, 2000, 58, 182-192.	5.2	144
222	Renal C3 synthesis in idiopathic membranous nephropathy: Correlation to urinary C5b-9 excretion. Kidney International, 2000, 57, 137-146.	5.2	28
223	Epidemiology of end-stage renal disease: International comparisons of renal replacement therapy. Kidney International, 2000, 57, S39-S45.	5.2	122
224	Clinical relevance of cytokine production in hemodialysis. Kidney International, 2000, 58, S104-S111.	5.2	120
225	Are lipid-dependent indicators of cardiovascular risk affected by renal transplantation?. Clinical Transplantation, 2000, 14, 139-146.	1.6	9
226	IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22–23. Nature Genetics, 2000, 26, 354-357.	21.4	291
227	To the birthday of Giuseppe D'Amico. Nephrology Dialysis Transplantation, 2000, 15, 129-129.	0.7	1
228	Treatment of glomerulonephritides associated with hepatitis C virus infection. Nephrology Dialysis Transplantation, 2000, 15, 34-38.	0.7	9
229	Tissue factor, plasminogen activator inhibitor-1, and thrombin receptor expression in human crescentic glomerulonephritis. American Journal of Kidney Diseases, 2000, 35, 726-738.	1.9	42
230	Renal expression of monocyte chemotactic protein-1 and epidermal growth factor in children with obstructive hydronephrosis. Journal of Pediatric Surgery, 2000, 35, 569-572.	1.6	24
231	IMMUNOLOGIC EVALUATION DURING THE FIRST YEAR OF LIFE OF INFANTS BORN TO CYCLOSPORINE-TREATED FEMALE KIDNEY TRANSPLANT RECIPIENTS. Transplantation, 2000, 69, 2049-2054.	1.0	86
232	Regenerative and Proinflammatory Effects of Thrombin on Human Proximal Tubular Cells. Journal of the American Society of Nephrology: JASN, 2000, 11, 1016-1025.	6.1	44
233	Thrombin: A Novel Renal Growth Factor. Nephron Experimental Nephrology, 1999, 7, 20-25.	2.2	14
234	Low-density lipoproteins enhance transforming growth factor-beta 1 (TGF-β1) and monocyte chemotactic protein-1 (MCP-1) expression induced by cyclosporin in human mesangial cells. Clinical and Experimental Immunology, 1999, 117, 355-360.	2.6	11

#	Article	IF	CITATIONS
235	Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells. Kidney International, 1999, 56, 461-470.	5.2	79
236	Acute renal failure in critically ill patients. Intensive Care Medicine, 1999, 25, 1188-1190.	8.2	8
237	Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet, The, 1999, 354, 359-364.	13.7	800
238	Angiotensin converting enzyme gene polymorphism in renal transplant patients with IgA nephropathy: relationship with graft function and prevalence of hypertension. Transplantation Proceedings, 1999, 31, 1357-1358.	0.6	5
239	Ramipril Inhibits in vitro Human Mesangial Cell Proliferation and Platelet-Derived Growth Factor Expression. Nephron Experimental Nephrology, 1999, 7, 229-235.	2.2	10
240	Renal Growth Factors: Past, Present and Future. American Journal of Nephrology, 1999, 19, 308-312.	3.1	18
241	Interleukin-6, interleukin-8 and monocyte chemotactic peptide-1 gene expression and protein synthesis are independently modulated by hemodialysis membranes. Kidney International, 1998, 54, 570-579.	5.2	40
242	Additive effect of cyclosporine and low density lipoproteins on transforming growth factor-l ² 1 and monocyte chemotactic protein-1 expression in human mesangial cells. Transplantation Proceedings, 1998, 30, 2051.	0.6	1
243	Survey of the Italian Registry of Renal Biopsies. Frequency of the renal diseases for 7 consecutive years. The Italian Group of Renal Immunopathology. Nephrology Dialysis Transplantation, 1997, 12, 418-426.	0.7	205
244	Long-term prognosis of Henoch-Schonlein nephritis in adults and children. Nephrology Dialysis Transplantation, 1997, 12, 2277-2283.	0.7	168
245	Posttransplant erythrocytosis: A possible nonerythropoietin-mediated mechanism. Transplantation Proceedings, 1997, 29, 223.	0.6	5
246	Monocyte recruitment in cryoglobulinemic membranoproliferative glomerulonephritis: A pathogenetic role for monocyte chemotactic peptide-1. Kidney International, 1997, 51, 155-163.	5.2	44
247	Report on the first meeting of the Chairmen of the National and International Registries. Kidney International, 1997, 52, 1422.	5.2	7
248	Progression of renal damage in human glomerulonephritides: Is there sleight of hand in winning the game?. Kidney International, 1997, 52, 1439-1457.	5.2	82
249	Hepatitis C virus-related proteins in kidney tissue from hepatitis C virus-infected patients with cryoglobulinemic membranoproliferative glomerulonephritis. Hepatology, 1997, 25, 1237-1244.	7.3	155
250	MONOCYTE CHEMOTACTIC PEPTIDE-1 EXPRESSION AND MONOCYTE INFILTRATION IN ACUTE RENAL TRANSPLANT REJECTION1. Transplantation, 1997, 63, 414-420.	1.0	121
251	INTERFERENCE OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS ON ERYTHROPOIESIS IN KIDNEY TRANSPLANT RECIPIENTS. Transplantation, 1997, 64, 913-918.	1.0	73
252	Urinary IL-6/EGF ratio: A useful prognostic marker for the progression of renal damage in IgA nephropathy. Kidney International, 1996, 50, 1990-2001.	5.2	94

#	Article	IF	CITATIONS
253	Expression of epidermal growth factor and its receptor in normal and diseased human kidney: An immunohistochemical and in situ hybridization study. Kidney International, 1996, 49, 656-665.	5.2	121
254	Bibliometric analysis of the scientific productivity of the Italian Society of Nephrology for a period of five consecutive years (1990-1994). Nephrology Dialysis Transplantation, 1996, 11, 2359-2360.	0.7	5
255	Urinary Epidermal Growth Factor Concentration in Patients Affected by ADPKD. Contributions To Nephrology, 1995, 115, 105-108.	1.1	3
256	Biosynthesis of C3 by human mesangial cells. Modulation by proinflammatory cytokines. Kidney International, 1995, 47, 829-836.	5.2	32
257	Immunogenetic aspects of primary IgA nephropathy. Kidney International, 1995, 48, 1998-2013.	5.2	39
258	Cultured Human Mesangial Cells Produce both Type 1 and Type 2 Plasminogen Activator Inhibitors. Thrombosis and Haemostasis, 1995, 74, 1516-1520.	3.4	4
259	Trapidil inhibits human mesangiai cell proliferation: Effect on PDGF β-receptor binding and expression. Kidney International, 1994, 46, 1002-1009.	5.2	56
260	Domenico Cotugno and His Interest in Proteinuria. American Journal of Nephrology, 1994, 14, 325-329.	3.1	11
261	Expression of platelet-derived growth factor receptors in normal and diseased human kidney. An immunohistochemistry and in situ hybridization study Journal of Clinical Investigation, 1994, 94, 50-58.	8.2	97
262	Primary IgA Nephropathy: The Relevance of Experimental Models in the Understanding of Human Disease. Nephron, 1992, 62, 373-381.	1.8	10
263	Complement Deficiency and Antibody Profile in Survivors of Meningococcal Meningitis due to common Serogroups in Italy. Scandinavian Journal of Immunology, 1992, 35, 589-596.	2.7	31
264	Chronic Renal Failure for Bilateral Spontaneous Kidney Rupture in a Case of Tuberous Sclerosis. American Journal of Nephrology, 1991, 11, 416-421.	3.1	12
265	Urinary procoagulant and fibrinolytic activity in human glomerulonephritis. Relationship with renal function. Kidney International, 1991, 39, 1213-1217.	5.2	15
266	Regional variation in C4 phenotype in patients with IgA nephropathy. Journal of Pediatrics, 1990, 116, S72-S77.	1.8	4
267	Report on the 2nd European Meeting on Complement in Human Disease. Complement and Inflammation, 1989, 6, 94-95.	0.7	0
268	Increased production of interleukin-2 and IL-2 receptor in primary IgA nephropathy. Kidney International, 1989, 35, 875-879.	5.2	47
269	Treatment of proteinuric idiopathic glomerulonephritides in adults: A retrospective survey. American Journal of Medicine, 1988, 85, 315-326.	1.5	53
270	Long term follow-up of women with hypertension in pregnancy. International Journal of Gynecology and Obstetrics, 1988, 27, 45-49.	2.3	21

#	Article	IF	CITATIONS
271	The Role of Polymeric IgA in Complement-Mediated Solubilization of IgG and IgA Immune Complexes. American Journal of Kidney Diseases, 1988, 12, 433-436.	1.9	6
272	A mulficentre study of flumequine in the treatment of urinary tract infections. Journal of Antimicrobial Chemotherapy, 1988, 21, 101-106.	3.0	8